Prescription Patterns, Initiation, and 5-Year Adherence to Adjuvant Hormonal Therapy Among Commercially Insured Patients With Breast Cancer

Tamoxifen and aromatase inhibitors (AIs) are used as adjuvant hormonal therapy (AHT) for early-stage hormone receptor–positive (HR+) breast cancer. Treatment for 5 years reduces cancer mortality by 30%. Despite this benefit, adherence to AHT has been suboptimal. Here, we evaluated AHT initiation and...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JCO Oncol Pract
Autors principals: Zhao, Hui, Lei, Xiudong, Niu, Jiangong, Zhang, Ning, Duan, Zhigang, Chavez-MacGregor, Mariana, Giordano, Sharon H.
Format: Artigo
Idioma:Inglês
Publicat: Wolters Kluwer Health 2021
Matèries:
ORIGINAL CONTRIBUTIONS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8257979/
https://ncbi.nlm.nih.gov/pubmed/33596096
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/OP.20.00248
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars